Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs

Kyle Blankenship

Despite its standing as pharma’s biggest cancer player, Roche has mostly stood pat on next-gen cell therapies that its competitors have gobbled up with gusto. Ready to finally make a splash of its own, Roche has inked a major deal to dive into the future.

Roche’s Genentech has signed a deal worth $150 million upfront and a total value of more than $3 billion to partner with Adaptimmune on off-the-shelf T cell therapies that marks the cancer giant’s first significant pipeline pivot into next-gen oncology drugs, the partners said Tuesday.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Can­cer gi­ant Roche splash­es in­to cell ther­a­py with $3B+ Adap­ti­m­mune deal for off-the-shelf drugs

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir